

## AB077. The expression and clinical significance of $\alpha$ -actinin-1 in prostate cancer and benign prostatic hyperplasia

Feng-Hong Cao

Department of Urology, the Affiliated Hospital of North China University of Science and Technology, Tangshan 064400, China

**Background:** To investigate the expression and clinical significance of  $\alpha$ -actinin-1 protein in prostate cancer and prostatic hyperplasia.

**Methods:** Collection all the clinical data of the patients of prostate cancer and prostatic hyperplasia treated in our school affiliated hospital between January 2007 and October 2014, according to certain criteria into a group filter. Immunohistochemistry method was used to detect the expression of  $\alpha$ -actinin-1 in 30 cases of prostate cancer (PCa) tissues and 30 cases of benign prostatic hyperplasia (BPH) tissues. Western blot method was used to detect the relative expression of  $\alpha$ -actinin-1 in 18 cases of PCa tissues and 20 cases of BPH tissues among the two groups.

**Results:** The result of Immunohistochemistry shows that the positive expression rate of  $\alpha$ -actinin-1 in PCa and BPH was 76.7% and 20% respectively. The difference was statistically significant ( $P < 0.01$ ). And the result of Western Plot shows that the expression of  $\alpha$ -actinin-1 in PCa tissues was significantly higher than that in BPH tissues. The difference was statistically significant ( $P < 0.05$ ). The expression of  $\alpha$ -actinin-1 in PCa has statistically significant with Gleason scores and T staging ( $P < 0.05$ ) instead of age, serum PSA, whether there is bone metastasis, whether there is lymph node metastasis ( $P > 0.05$ ).

**Conclusions:** The expression of  $\alpha$ -actinin-1 in PCa tissues was significantly higher than that in BPH tissues, and there may exist certain relationship with Gleason scores and T staging.

**Keywords:** Prostate cancer (PCa); benign prostatic hyperplasia (BPH);  $\alpha$ -actinin-1

doi: 10.21037/tau.2017.s077

Cite this abstract as: Cao FH. The expression and clinical significance of  $\alpha$ -actinin-1 in prostate cancer and benign prostatic hyperplasia. *Transl Androl Urol* 2017;6(Suppl 3):AB077. doi: 10.21037/tau.2017.s077

## AB078. Knockdown of SPC25 inhibits cell proliferation and cycle progression in prostate cancer

Feilun Cui, Jiangpeng Hu, Jian Tan, Huaming Tang

Department of Urology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212000, China

**Abstract:** Prostate cancer (PCa) was one of the most commonly diagnosed malignant cancers in males in China. Cell-cycle aberration was a hallmark of cancer. SPC25, a component of Ndc80 complex, played an important role in regulating mitotic chromosome segregation. However, the functional roles of SPC25 in prostate cancer were still poorly understood. Our study showed for the first time that SPC25 was significantly upregulated in prostate cancer. To explore the molecular function roles of SPC25, we performed loss of function assay and found SPC25 knockdown inhibited cell proliferation and induced the decrease in S phase and the increase in G2/M phase. Furthermore, SPC25 knockdown promoted apoptosis of prostate cancer cells. Of note, bioinformatics analysis also revealed multiple functional roles of SPC25 in regulating cell proliferation, apoptosis, invasion, role of tissue factor in cancer, TGF- $\beta$  signaling, and sumoylation pathway in PCa. Here, we also evaluated possible prognostic value of SPC25 using TCGA RNA-seq data and we found showed SPC25 was upregulated in high pathology stage PCa. Kaplan-Meier analysis showed that Lower SPC25 expression level was associated with better survival of PCa patients. All these results suggest that SPC25 play an oncogenic role in PCa and could act as a novel diagnostic and therapeutic target for prostate cancer.